Pembina Pipeline Corporation CUM PFD SER A 21
PMMBF News Today: Stay Updated with the Latest Pembina Pipeline Corporation CUM PFD SER A 21 News in Real Time
Find PMMBF news now at Meyka AI. Stay informed with the latest Pembina Pipeline Corporation CUM PFD SER A 21 stocks updates, including price news, market analysis, and expert insights.
8015.T Stock Drops 1.68% as Toyota Tsusho Reports May 2026 Earnings
Toyota Tsusho (8015.T) falls 1.68% to ¥6,101 on JPX pre-market. EPS at 348.29, PE 18.32. Meyka rates B+.
PHRX.CN stock surges 50% on April 30, 2026 amid market recovery
PHRX.CN stock jumps 50% to C$0.015 on CNQ. Pharmadrug Inc. shows strong momentum in specialty pharma sector.
WNBD Stock Surges 9900% on April 30, 2026 – Winning Brands Analysis
WNBD stock surged 9900% to $0.0001 on April 30, 2026. Winning Brands trades on PNK with extreme penny stock volatility and minimal volume.
BCPL.BO stock surges 21% on April 30 as railway electrification gains momentum
BCPL.BO stock rallies 21% to INR 85.64 on BSE. Railway infrastructure specialist gains on strong technical signals and sector tailwinds.
GDX.DE General Dynamics Earnings Beat: Strong Q1 2026 Results
General Dynamics (GDX.DE) beats earnings estimates with $3.55 EPS and $11.67B revenue on April 29, 2026.
OERL.SW stock surges 4.13% on April 30, 2026 amid industrial machinery demand
OERL.SW stock climbs 4.13% to CHF 3.40 on SIX. OC Oerlikon trades 845,936 shares as industrial machinery sector gains momentum.
CYW.SI Stock Drops 8.8% on SES: TrickleStar Limited Falls to S$0.031
TrickleStar Limited (CYW.SI) falls 8.8% to S$0.031 on Singapore Exchange. Energy optimization stock faces profitability challenges.
SBUX Maintains Buy Rating at Deutsche Bank, April 2026
Deutsche Bank maintains Buy rating on Starbucks, raises price target to $120 from $114 on April 29, 2026.
Eli Lilly ($LLY) Raises Annual Forecasts as GLP-1 Drugs Fuel Growth
Eli Lilly and Company ($LLY) raised its full-year 2026 forecast in April 2026 after strong demand for its GLP-1 drugs. The company reported better-than-expected Q1 2026 results, driven by rapid sales of Mounjaro and Zepbound. These medicines are reshaping the obesity and diabetes market worldwide. Investor confidence has surged as growth momentum continues. The update…